GeneSightRx is a clinically focused technology developed by AssureRx Health that measures and analyzes important genomic variants affecting the metabolism and response to behavioral health medications in individual patients. These laboratory-developed genomic tests serve as a clinical treatment support tool for your practice, providing you with objective genetic-based patient information in advance of making a medication decision for your patient. Knowing a patient's genetic profile and having it available in a clear and easy to interpret report can help you understand which medications the patient would metabolize properly and help inform treatment choices unique to each patient.
AssureRx Health products powered by GeneSightRx technology include:
- This test analyzes six genes that may affect a patient’s response to antidepressant and antipsychotic medications. Four pharmacokinetic genes from the Cytochrome P450 family and two pharmacodynamic genes related specifically to the serotonin system are genotyped.
- This test analyzes three genes that can affect a patient’s response to ADHD medications, including stimulant and non-stimulant medications. The test includes a pharmacokinetic gene from the Cytochrome P450 family and two pharmacodynamic genes related to the regulation of neurotransmitters.
- This test analyzes two genes that can affect a patient’s response to opioid medications. A pharmacokinetic gene from the Cytochrome P450 (CYP450) family and one pharmacodynamic gene that mediates the analgesic effects of commonly prescribed opioid medications. In addition, the report can predict the influence of CYP450 2D6 on both the parent drug and active metabolite levels of opioids obtained through urine drug testing.
If you are a clinician interested in ordering a GeneSightRx test for a patient, please navigate to our Clinicians page for registration and ordering information.
If you are a clinician and are searching for the results for a patient, or if you are already registered and wish to order a new test for a patient, please click here.